170 related articles for article (PubMed ID: 28691153)
1. Telomere shortening, TP53 mutations and deletions in chronic lymphocytic leukemia result in increased chromosomal instability and breakpoint clustering in heterochromatic regions.
Thomay K; Fedder C; Hofmann W; Kreipe H; Stadler M; Titgemeyer J; Zander I; Schlegelberger B; Göhring G
Ann Hematol; 2017 Sep; 96(9):1493-1500. PubMed ID: 28691153
[TBL] [Abstract][Full Text] [Related]
2. Telomere status in chronic lymphocytic leukemia with TP53 disruption.
Guièze R; Pages M; Véronèse L; Combes P; Lemal R; Gay-Bellile M; Chauvet M; Callanan M; Kwiatkowski F; Pereira B; Vago P; Bay JO; Tournilhac O; Tchirkov A
Oncotarget; 2016 Aug; 7(35):56976-56985. PubMed ID: 27486974
[TBL] [Abstract][Full Text] [Related]
3. Telomere length and its correlation with gene mutations in chronic lymphocytic leukemia in a Korean population.
Song DY; Kim JA; Jeong D; Yun J; Kim SM; Lim K; Park SN; Im K; Choi S; Yoon SS; Lee DS
PLoS One; 2019; 14(7):e0220177. PubMed ID: 31335885
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia.
Xu W; Li JY; Wu YJ; Yu H; Shen QD; Li L; Fan L; Qiu HX
Leuk Res; 2008 Jul; 32(7):1071-7. PubMed ID: 18035414
[TBL] [Abstract][Full Text] [Related]
5. Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome.
Steinbrecher D; Jebaraj BMC; Schneider C; Edelmann J; Cymbalista F; Leblond V; Delmer A; Ibach S; Tausch E; Scheffold A; Bloehdorn J; Hallek M; Dreger P; Döhner H; Stilgenbauer S
Leuk Lymphoma; 2018 Jul; 59(7):1614-1623. PubMed ID: 29063805
[TBL] [Abstract][Full Text] [Related]
6. Dissecting the role of TP53 alterations in del(11q) chronic lymphocytic leukemia.
Quijada-Álamo M; Pérez-Carretero C; Hernández-Sánchez M; Rodríguez-Vicente AE; Herrero AB; Hernández-Sánchez JM; Martín-Izquierdo M; Santos-Mínguez S; Del Rey M; González T; Rubio-Martínez A; García de Coca A; Dávila-Valls J; Hernández-Rivas JÁ; Parker H; Strefford JC; Benito R; Ordóñez JL; Hernández-Rivas JM
Clin Transl Med; 2021 Feb; 11(2):e304. PubMed ID: 33634999
[TBL] [Abstract][Full Text] [Related]
7. An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness.
Rigolin GM; Formigaro L; Cavallari M; Quaglia FM; Lista E; Urso A; Guardalben E; Martinelli S; Saccenti E; Bassi C; Lupini L; Bardi MA; Volta E; Tammiso E; Melandri A; Negrini M; Cavazzini F; Cuneo A
Oncotarget; 2017 Apr; 8(17):28008-28020. PubMed ID: 28427204
[TBL] [Abstract][Full Text] [Related]
8. Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes.
Rampazzo E; Bonaldi L; Trentin L; Visco C; Keppel S; Giunco S; Frezzato F; Facco M; Novella E; Giaretta I; Del Bianco P; Semenzato G; De Rossi A
Haematologica; 2012 Jan; 97(1):56-63. PubMed ID: 21933855
[TBL] [Abstract][Full Text] [Related]
9. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype.
Dicker F; Herholz H; Schnittger S; Nakao A; Patten N; Wu L; Kern W; Haferlach T; Haferlach C
Leukemia; 2009 Jan; 23(1):117-24. PubMed ID: 18843282
[TBL] [Abstract][Full Text] [Related]
10. TP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemia.
Malcikova J; Pavlova S; Kozubik KS; Pospisilova S
Hum Mutat; 2014 Jun; 35(6):663-71. PubMed ID: 24415659
[TBL] [Abstract][Full Text] [Related]
11. Telomere shortening associated with increased genomic complexity in chronic lymphocytic leukemia.
Dos Santos P; Panero J; Palau Nagore V; Stanganelli C; Bezares RF; Slavutsky I
Tumour Biol; 2015 Nov; 36(11):8317-24. PubMed ID: 26008147
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
[TBL] [Abstract][Full Text] [Related]
13. Aberrant nuclear p53 expression predicts hemizygous 17p (TP53) deletion in chronic lymphocytic leukemia.
Chang H; Jiang AM; Qi CX
Am J Clin Pathol; 2010 Jan; 133(1):70-4. PubMed ID: 20023260
[TBL] [Abstract][Full Text] [Related]
14. Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations.
Rigolin GM; Saccenti E; Bassi C; Lupini L; Quaglia FM; Cavallari M; Martinelli S; Formigaro L; Lista E; Bardi MA; Volta E; Tammiso E; Melandri A; Urso A; Cavazzini F; Negrini M; Cuneo A
J Hematol Oncol; 2016 Sep; 9(1):88. PubMed ID: 27633522
[TBL] [Abstract][Full Text] [Related]
15. TP53 mutations are early events in chronic lymphocytic leukemia disease progression and precede evolution to complex karyotypes.
Lazarian G; Tausch E; Eclache V; Sebaa A; Bianchi V; Letestu R; Collon JF; Lefebvre V; Gardano L; Varin-Blank N; Soussi T; Stilgenbauer S; Cymbalista F; Baran-Marszak F
Int J Cancer; 2016 Oct; 139(8):1759-63. PubMed ID: 27270786
[TBL] [Abstract][Full Text] [Related]
16. Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders. Clinico-biological significance.
Cuneo A; Bigoni R; Rigolin GM; Roberti MG; Bardi A; Cavazzini F; Milani R; Minotto C; Tieghi A; Della Porta M; Agostini P; Tammiso E; Negrini M; Castoldi G
Haematologica; 2002 Jan; 87(1):44-51. PubMed ID: 11801464
[TBL] [Abstract][Full Text] [Related]
17. TP53 mutation and survival in chronic lymphocytic leukemia.
Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S
J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090
[TBL] [Abstract][Full Text] [Related]
18. Chronic lymphocytic leukemia with isochromosome 17q: An aggressive subgroup associated with TP53 mutations and complex karyotypes.
Collado R; Puiggros A; López-Guerrero JA; Calasanz MJ; Larráyoz MJ; Ivars D; García-Casado Z; Abella E; Orero MT; Talavera E; Oliveira AC; Hernández-Rivas JM; Hernández-Sánchez M; Luño E; Valiente A; Grau J; Portal I; Gardella S; Salgado AC; Giménez MT; Ardanaz MT; Campeny A; Hernández JJ; Álvarez S; Espinet B; Carbonell F
Cancer Lett; 2017 Nov; 409():42-48. PubMed ID: 28888994
[TBL] [Abstract][Full Text] [Related]
19. Evolution of TP53 abnormalities during CLL disease course is associated with telomere length changes.
Olbertova H; Plevova K; Pavlova S; Malcikova J; Kotaskova J; Stranska K; Spunarova M; Trbusek M; Navrkalova V; Dvorackova B; Tom N; Pal K; Jarosova M; Brychtova Y; Panovska A; Doubek M; Pospisilova S
BMC Cancer; 2022 Feb; 22(1):137. PubMed ID: 35114947
[TBL] [Abstract][Full Text] [Related]
20. TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia.
Zainuddin N; Murray F; Kanduri M; Gunnarsson R; Smedby KE; Enblad G; Jurlander J; Juliusson G; Rosenquist R
Leuk Res; 2011 Feb; 35(2):272-4. PubMed ID: 20870288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]